Lexeo Therapeutics, Inc. to acquire Mantle Therapeutics Inc.

Lexeo Therapeutics, Inc. has agreed to acquire Mantle Therapeutics Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 22 September 2026 and subsequently completed on 29 September 2026. Both the buyer and the target are based in the United States. The headline offer for the deal is valued at eight million three hundred thousand US dollars. The consideration structure for this acquisition includes a combination of cash, shares, and an earn-out component. This arrangement allows for a mixed payment method, blending immediate liquidity with long-term equity alignment and performance-based compensation. The deal represents a consolidation of assets between two US-based entities in the healthcare industry. The specific terms regarding the split between cash and equity were not detailed in the available data, but the inclusion of an earn-out suggests future milestones may influence the final payout. The process moved swiftly from announcement to completion, indicating a streamlined regulatory and internal approval path for this cross-border, or rather domestic, US transaction. The completed status confirms that all necessary conditions were met within the week following the public announcement.